For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its potential is Ohtuvayre, a blockbuster drug that regulators approved last year ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

LONDON, UK and BUDAPEST, HUNGARY, Aug. 4, 2025 /PRNewswire/ -- Turbine, a leading developer of cell simulations with AI, ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

U.S. FDA Accepts New Drug Application for Merck’s DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.

Valued at $199.1 billion by market cap, Merck & Co., Inc. (MRK) is a leading American biopharmaceutical company based in ...

Before joining Merck, he advised Fortune 500 clients as a consultant with McKinsey & Company. He has also served on the Healthcare Leadership Council in Washington, DC, where he actively engaged ...

Institutions Time frame: 1 March 2024 - 28 February 2025 Home Institution outputs Merck & Co, United States of America (USA) Profile Research Collaboration Job finder Relationships Related News ...

Merck & Co. expects to lose $200 million due to already-announced tariffs in 2025 amid the US-China trade war. The company's first-quarter results beat estimates, with sales of $15.5 billion and ...

March 20, 2025 at 12:00 AM Email Share Print Case Digest Summary ...